Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.35 Analyst target: $18.88 Upside: 334.02%
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.